| Name | Title | Contact Details |
|---|
For over 120 years, Parr Instrument Company has been designing, manufacturing, and selling high quality laboratory instruments and apparatus for conducting chemical reactions and tests under heat and pressure and for testing fuels. Parrs extensive product line includes stirred reactors, pressure vessels, and high pressure tubular reactors for the study of catalytic and non-catalytic reactions in batch, continuous-flow, and multiple/parallel operation for the chemical, polymer, biofuels, hydrometallurgical, pharmaceutical, petroleum, and petrochemical industries. Custom designed complex reactor systems, built to the customers specifications and requirements are also provided. Parrs oxygen combustion calorimeters are used for the determination of the heat of combustion in solid, liquid, and refuse-derived fuels for the energy, educational, coal, and fuel testing industries. Parr also offers sample preparation vessels for extraction, digestion, and hydrothermal synthesis, as well as a line of vessels for cell disruption by nitrogen decompression.
The impact of disasters—natural or otherwise—can leave even the most robust entities vulnerable, causing uncertainty over their future. This constant threat magnifies stress, strains resources, and hampers growth, making resilience more crucial than ever. At Tidal Basin Group, we tackle these challenges head-on. As architects of resilience, we transform vulnerability into strength through innovative thinking and integrated solutions in program management, technology and emergency consulting. We listen, consider diverse perspectives, and equip you with the tools to redefine resilience. Our mission is to empower organizations and communities to rebound from challenges, and create a future where resilience is the backbone of every strategy—helping everyone to Be stronger than before®.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.